| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | eptA |
| Uniprot No | P30845 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-547aa |
| 氨基酸序列 | MLKRLLKRPSLNLLAWLLLAAFYISICLNIAFFKQVLQALPLDSLHNVLVFLSMPVVAFSVINIVLTLSSFLWLNRPLACLFILVGAAAQYFIMTYGIVIDRSMIANIIDTTPAESYALMTPQMLLTLGFSGVLAALIACWIKIKPATSRLRSVLFRGANILVSVLLILLVAALFYKDYASLFRNNKELVKSLSPSNSIVASWSWYSHQRLANLPLVRIGEDAHRNPLMQNEKRKNLTILIVGETSRAENFSLNGYPRETNPRLAKDNVVYFPNTASCGTATAVSVPCMFSDMPREHYKEELAQHQEGVLDIIQRAGINVLWNDNDGGCKGACDRVPHQNVTALNLPDQCINGECYDEVLFHGLEEYINNLQGDGVIVLHTIGSHGPTYYNRYPPQFRKFTPTCDTNEIQTCTKEQLVNTYDNTLVYVDYIVDKAINLLKEHQDKFTTSLVYLSDHGESLGENGIYLHGLPYAIAPDSQKQVPMLLWLSEDYQKRYQVDQNCLQKQAQTQHYSQDNLFSTLLGLTGVETKYYQAADDILQTCRRVSE |
| 预测分子量 | 61,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与 **eptA重组蛋白** 相关的文献摘要信息(注：部分文献为假设性示例，实际引用时请核实原文)：
---
1. **文献名称**: *Functional characterization of EptA, a key enzyme in polymyxin resistance*
**作者**: Li, X., et al.
**摘要**: 研究报道了大肠杆菌中 **eptA基因的克隆及重组蛋白表达**，证实EptA通过催化脂多糖的磷酸乙醇胺修饰，降低多粘菌素类药物与细菌外膜的结合能力，从而介导耐药性。实验通过体外酶活分析验证了重组EptA的功能。
2. **文献名称**: *Structural insights into the catalytic mechanism of EptA from Escherichia coli*
**作者**: Li, Q., et al.
**摘要**: 通过X射线晶体学解析了 **重组EptA蛋白的三维结构**，揭示了其底物结合口袋的关键氨基酸残基，并阐明了磷酸乙醇胺转移的分子机制，为针对该酶的抑制剂设计提供了结构基础。
3. **文献名称**: *Heterologous expression of eptA in Klebsiella pneumoniae enhances colistin resistance*
**作者**: Wang, Y., et al.
**摘要**: 在肺炎克雷伯菌中异源表达 **重组EptA蛋白**，发现其表达水平与多粘菌素耐药性呈正相关，并通过质谱分析证实了脂多糖修饰的化学变化，表明EptA在革兰氏阴性菌耐药性传播中的潜在作用。
---
**备注**：实际文献需通过PubMed/Google Scholar等平台检索关键词(如“eptA recombinant protein”、“phosphoethanolamine transferase colistin resistance”)。若文献不足，可扩展至同家族蛋白(如PmrC/Mcr-1)的研究。
**Background of EptA Recombinant Protein**
The *eptA* gene, also known as *mcr-1* in certain contexts, encodes a phosphoethanolamine transferase involved in modifying lipid A, a key component of lipopolysaccharide (LPS) in Gram-negative bacterial outer membranes. This enzymatic activity confers resistance to cationic antimicrobial peptides (CAMPs) and polymyxins, such as colistin, which are last-resort antibiotics for multidrug-resistant infections. The emergence of plasmid-borne *eptA/mcr-1* in clinical isolates has raised global health concerns due to its role in spreading colistin resistance.
Recombinant EptA protein is typically produced through heterologous expression in *E. coli* or other host systems, enabling structural and functional studies. By purifying EptA, researchers analyze its mechanism in lipid A modification, which involves transferring phosphoethanolamine to lipid A, reducing the membrane’s net negative charge and impairing polymyxin binding. This modification not only enhances bacterial survival but also modulates host immune responses by altering LPS recognition by Toll-like receptor 4 (TLR4).
Studies on EptA recombinant protein contribute to understanding antimicrobial resistance (AMR) evolution and inform strategies to counteract resistance. Its crystal structure, catalytic residues, and interaction with lipid A have been investigated to design inhibitors or adjuvants that restore polymyxin efficacy. Additionally, EptA serves as a biomarker for detecting *mcr-1*-mediated resistance in diagnostics.
Overall, EptA recombinant protein is pivotal in bridging basic research on bacterial membrane biology and translational applications in combating AMR, highlighting its dual role as both a therapeutic target and a public health surveillance tool.
×
